BioSpace Insights
The BioSpace Insights team performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.
Latest from Insights
Expansion across its network will mean hundreds of new employees in Cincinnati, increased ability to get complex medicines to patients and more.
Surviving and Thriving in the Never-ending Biotech Downturn
LIVE WEBINAR | MAY 20 | 2PM–3PM EST
The rumors of biotech’s return have been greatly exaggerated. Despite some M&A sparks, a handful of mega fundraises and a trickle of IPOs, the biotech industry continues to climb out of a multi-year down period. So how does a company thrive in this environment?
BioSpace sits down with four NextGen companies doing just that, to hear about ways they are defying the odds to churn out clinical data that may finally provide the industry with a ladder out.
LIVE WEBINAR | MAY 20 | 2PM–3PM EST
The rumors of biotech’s return have been greatly exaggerated. Despite some M&A sparks, a handful of mega fundraises and a trickle of IPOs, the biotech industry continues to climb out of a multi-year down period. So how does a company thrive in this environment?
BioSpace sits down with four NextGen companies doing just that, to hear about ways they are defying the odds to churn out clinical data that may finally provide the industry with a ladder out.
Listen to Denatured
Unravel the business of science with BioSpace.
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss the industry’s need to catch up with women’s health issues and the innovative lead the APAC region has taken in clinical trials.
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh speculate on the impending Trump administration, discuss current challenges faced by CEOs and weigh investment in GLP-1s.
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss how a slow and steady pace is a continuation of the pattern we have seen throughout the last three years.
Webinars
This webinar explores the pivotal role of patent data in overcoming the data challenges faced by generative AI models in drug discovery, particularly for biologics. Watch now.
BioSpace at 2025 SCOPE Summit
Events
In this live panel discussion, speakers focused on the EU AI Act’s global regulatory implications for medical devices & QARA’s future. An executive summary is available.
- BIO International Convention: June 16-19, 2025 | Boston, MA
- Bioprocessing Summit: August 18-21, 2025 | Boston, MA
- Meeting on the Mesa: October 6-8, 2025 | Phoenix, AZ
BioSpace x DIA
The groundwork being done in 2024 is building the foundation for global collaboration in the future.
DRUG DEVELOPMENT
DRUG DEVELOPMENT
FROM BIOSPACE INSIGHTS
Before companies and investors look towards the future, they must first understand the opportunities and challenges AI presents to them. From the benefits included in advancing processes to cybersecurity hazards, AI innovation is a balanced scale of oppportunities and risks.
In this episode, Lori and guests discuss practical approaches regarding artificial intelligence and investor and industry confidence in its current state.
In this episode, the third and final conversation of our mini-series on diversity in clinical trials, Lori and guests discuss framing strategies designed to protect DEI initiatives from legal challenges.
Lori and guests address clinical trial design, which if done without careful consideration of the patient population can exclude patients from clinical trials instead of being inclusive.
At a private event held amid the fallout from the CrowdStrike incident, cybersecurity issues took a front seat, with the consequences of the evolving EU AI Act and the Loper Bright and Corner Post decisions also raising concerns for quality assurance and regulatory affairs professionals.
In this episode, Lori and guests discuss the pursuit of adequate representation and how clinical trials are being shaped by the legal environment they operate within.
This is the third episode of Denatured’s discussion on diversity, equity and inclusion. Here, our guests discuss imperatives around access and accountability.
This week on Denatured, Head of Insights Lori Ellis and guests discuss the implications of not addressing the DE&I data gaps for the future.
This week on Denatured, Head of Insights Lori Ellis and guests discuss the persisting challenges of diversity, equity and inclusion when designing clinical trials.
BioSpace’s third report on diversity, equity, inclusion and belonging in life sciences examines dramatic shifts in attitude around diversity initiatives.